

## **SUPPLEMENTARY DATA**

**Supplementary Table S1.** Association between HER2-low (HER2 1+ versus HER2 1+) and pCR

**Supplementary Table S2.** Clinicopathological characteristics of the tumours after surgery

**Supplementary Table S3.** D-DFS according to HER2 status

**Supplementary Table S4.** Evolution of PLR and NLR at baseline and after treatment

**Supplementary Table S5.** Outcomes according to baseline PLR et HER2 status

**Supplementary Figure S1.** Outcomes according to baseline PLR. A) OS and B) I-DFS

**Supplementary Table S1. Association between HER2-low (HER2 1+ versus HER2 1+) and pCR.**

	HER2 1+ (N = 95)	HER 2+ (N = 31)	p-value
<b>pCR</b>			<i>0.673</i>
No	60 (63.2%)	21 (67.7%)	
Yes	35 (36.8%)	10 (32.3%)	

**Supplementary Table S2. Clinicopathological characteristics after surgery.**

	HER2-0 (N = 323)	HER2-low (N = 126)	Total (N = 449)
<b>mSBR grade</b>			
Grade II	5/38 (13.2%)	1/10 (10.0%)	6/48 (12.5%)
Grade III	33/38 (86.8%)	9/10 (90.0%)	42/48 (87.5%)
<b>RE</b>			
0	91/97 (93.8%)	36/39 (92.3%)	127/136 (93.4%)
1-10%	6/97 (6.2%)	3/39 (7.7%)	9/136 (6.6%)
<b>IHC HER2</b>			
0	83/88 (94.3%)	18/38 (47.4%)	101/126 (80.2%)
1+	4/88 (4.5%)	15/38 (39.5%)	19/126 (15.1%)
2+	1/88 (1.1%)	5/38 (13.2%)	6/126 (4.8%)
<b>Ki67 (%)</b>			
Median (Q1, Q3)	31.0 (8.0, 50.0)	52.0 (30.0, 70.0)	34.0 (10.0, 60.0)
<b>TILs</b>			
Yes	103/315 (32.7%)	37/124 (29.8%)	140/439 (31.9%)
<b>Interval response imaging</b>			
Stable disease	87/213 (40.8%)	28/88 (31.8%)	115/301 (38.2%)
Progress	5/213 (2.3%)	3/88 (3.4%)	8/301 (2.7%)
Partial or complete response	121/213 (56.8%)	57/88 (64.8%)	178/301 (59.1%)

**Supplementary Table S3.** D-DFS according to HER2 status.

	events/n	5 years D-DFS rate [95%CI]
<b>HER2</b>		
HER2 0	97/316	68.5% [62.7;73.6]
HER2 1+ ou 2+	49/121	63.1% [53.7;71.1]

**Supplementary Table S4.** Evolution of PLR at baseline and after treatment.

	Median difference (after – before CT)	Ratio (after/ before CT)	Evolution rate %	P value (paired test*)
<b>PLR</b>				
Median (range)	110.3 (-274.5; 1412.4)	1.8 (0.3; 9.3)	75.5 (-71.7, 826.4)	<b>&lt;0.001</b>
Missing	51	51	51	

\*Wilcoxon signed Rank test; CT: chemotherapy

**Supplementary Table S5.** Outcomes according to baseline PLR and HER2 status.

<b>OS</b>					
	n	HR [CI 95%]	p	HR [CI 95%]	p
<b>Baseline PLR</b>					
--- ≥ 190					
HER2-0	60	1.00 (ref)		2.28 [1.40;3.71]	0.001
HER2-low	37	0.54 [0.27;1.09]	0.085	1.24 [0.66;2.33]	0.508
— < 190					
HER2-0	224	0.44 [0.27;0.71]	0.001	1.00 (ref)	
HER2-low	76	0.73 [0.42;1.25]	0.246	1.65 [1.05;2.62]	0.031
<b>i-DFS</b>					
	n	HR [CI 95%]	p	HR [CI 95%]	p
<b>Baseline PLR</b>					
--- ≥ 190					
HER2-0	60	1.00 (ref)		2.03 [1.31;3.16]	0.002
HER2-low	37	0.58 [0.31;1.10]	0.094	1.18 [0.68;2.08]	0.554
— < 190					
HER2-0	224	0.49 [0.32;0.77]	0.002	1.00 (ref)	
HER2-low	76	0.74 [0.45;1.23]	0.249	1.51[1.00;2.29]	0.050

Supplementary Figure S1. Outcomes according to baseline PLR. (A) OS and (B) I-DFS.

